Navigating a life sciences market marked by relentless innovation, shifting deal dynamics, and world aggressive pressures requires greater than technical experience — it calls for perspective, agility, and a eager eye on the place development is accelerating. That’s exactly the vantage level that main companions on this space have to carry to the desk of their work.
From upticks in strategic M&A exercise to burgeoning drug growth hugs throughout the Asia-Pacific area, how are these developments reshaping strategic priorities for firms and buyers? Who higher to ask than the leaders of a outstanding world life sciences observe group?
I not too long ago had the pleasure of chatting with Michael Cohen and Adam Schoen, co-leaders of Brown Rudnick’s International Life Sciences Group, to get their ideas on the matter. Their work spans the total spectrum of company transactions and sector-defining development tales. Here’s a (calmly edited and condensed) write-up of our vigorous dialog on their ever-evolving observe space
Staci Zaretsky (SZ): What key developments are you seeing proper now in life sciences M&A exercise?
Michael Cohen & Adam Schoen (MC & AS): We’ve seen a gradual uptick in M&A and broader company growth exercise (together with licensing and collaboration/co-development transactions) in latest quarters and that momentum has continued by the second half of 2025. Massive pharmaceutical firms stay targeted on alternatives to replenish their pipelines as current merchandise are coming off-patent over the subsequent few years. Whereas IPO exercise has elevated towards year-end, M&A stays the first exit technique for all times science firms in late 2025.
SZ: Which areas inside life sciences are producing essentially the most development and funding curiosity?
MC & AS: Investor curiosity stays robust in biologics, particularly immunotherapies. In 2025, we noticed a renewed deal with antibody/drug conjugates and important funding in firms growing multi-specific antibody merchandise (e.g., bi-specific and tri-specific antibody merchandise). Key areas attracting funding embrace most cancers, non-cancerous inflammatory problems, neurology, and GLP1/GIPR associated indications.
SZ: How is the momentum within the Asia-Pacific market shaping innovation and dealmaking on this sector?
MC & AS: The Asia-Pacific market drove a considerable share of transactional exercise within the first half of 2025 and maintained a sturdy contributor within the second half. The area’s rising affect will proceed to form world life science dealmaking dynamics in 2026.
SZ: What are the principle authorized or regulatory challenges you’re navigating in life sciences transactions?
MC & AS: With the expansion in offers from the Asia-Pacific market, one of many major challenges is balancing licensors’ want to retain Asia-Pacific rights with licensees’ want for rest-of-world rights. That is particularly the case when a licensor has a platform, and a want to undertake a number of transactions. Structuring agreements to align these pursuits stays a vital focus.
SZ: What alternatives ought to life sciences firms be prioritizing now to place themselves for strategic development or future exits?
MC & AS: Scientific information stays the first catalyst for financing, partnerships, and M&A exercise. Our most profitable purchasers have oriented round environment friendly use of capital and a streamlined strategy for scientific analysis to provide a knowledge package deal that drives funding, collaboration, and M&A. The Asia-Pacific’s regulatory setting has additionally enabled speedy information era, providing a aggressive benefit. Corporations ought to prioritize producing high-quality scientific information rapidly to draw consideration from buyers, strategic companions, and potential acquirers.
On behalf of everybody right here at Above the Regulation, we’d wish to thank Michael Cohen and Adam Schoen of Brown Rudnick for taking the time to assist reply some urgent questions on a life sciences market the place innovation cycles are dashing up and capital is on the transfer.
Staci Zaretsky is the managing editor of Above the Regulation, the place she’s labored since 2011. She’d love to listen to from you, so please be at liberty to email her with any suggestions, questions, feedback, or critiques. You’ll be able to comply with her on Bluesky, X/Twitter, and Threads, or join together with her on LinkedIn.
